Four different insiders at Orchestra BioMed Holdings, Inc. (OBIO) bought company stock in the same reporting window, and together they put $6.13 million into the shares. The transaction date on our tables is November 9th, 2026. Clusters of this kind are worth separating from single-name purchases, because four distinct filers acting in the same period is a different signal than one person adding to a position.

The names on the filings are Fain Eric S, Hochman David P, RTW INVESTMENTS, LP and Taylor Andrew Lawrence. Fain Eric S is an individual filer, not an institution, which matters for how these entries are read: a person is buying with personal funds rather than deploying a fund mandate. RTW INVESTMENTS, LP appears alongside the individuals in the same group of filings.

Orchestra BioMed sits in the Surgical & Medical Instruments & Apparatus sector, a corner of the market where development timelines are long and where the people closest to a program tend to have a clearer view of where it stands than the tape does. That is context, not a conclusion. The filings record purchases and nothing more.

On the composition of the group: three of the four filers are named individuals and one is a firm. Insider disclosure rules capture officers, directors and holders above the ownership threshold, so a mixed group like this one is common at companies where a specialist investor also holds a board-linked position. We do not assign roles here beyond what the filings carry.

Timing is the cleanest fact in the set. All of the activity carries the November 9th, 2026 date, so this was not a drip of purchases spread across months. It was concentrated. For readers tracking OBIO, the last price on our tables is $6.97, which is the reference point for sizing what $6.13 million represents at the current quote.

What to weigh against it. Insider buying is one input and it is a backward-looking one, since Form 4s are filed after the fact. Small-cap medical device shares can move sharply on trial updates, partnership news and financing decisions, and none of that is visible in a purchase record. A cluster buy also says nothing about how long any of the four filers intend to hold. Readers should also note that purchases by an investment firm and purchases by an individual carry different motivations, even when they land on the same date.

The useful takeaway is narrow and factual: four insiders, $6.13 million, one date, one ticker. Everything past that is interpretation, and the filings do not supply it.

All figures in this article come from Form 4 filings submitted to the Securities and Exchange Commission and reconciled against our own insider transaction tables.

For the full insider history, ownership breakdown and transaction log on this name, see /companies/OBIO.